We reported a patient with antiphospholipid syndrome (APS) secondary to systemic lupus erythematosus (SLE) who suffered from myocardial infarction and graft occlusion after coronary artery bypass surgery. Our patient illustrates the impact of accelerated atherosclerosis in patients with SLE and APS and the importance of early institution of antithrombotic therapies. In this article, the treatment of APS is summarized. Although the main stay of treatment is anticoagulation, there is emerging evidence to support rituximab as an option for "refractory" cases of APS.
use, SLE disease duration, and disease activity all play parts. However, SLE itself confers the greatest risk for premature CHD. The underlying mechanisms include dysregulation of T cell and B cell populations, increased circulating inflammatory cytokines, a proatherogenic lipid profile, and so on. While both primary and secondary antiphospholipid syndrome (APS) usually present with recurrent miscarriages or other thromboembolic phenomenon, severe coronary artery disease requiring cardiac interventions are a rare event. We hereby reported a case of APS secondary to SLE in which the patient suffered from myocardial infarction and graft occlusion after coronary artery bypass surgery.
Case Report
A previously healthy, 37 years old, non-smoker, Chinese gentleman was diagnosed with SLE in 1994. He presented with intermittent fever, facial rash, and arthralgia. Although initial blood tests revealed leucopenia, subsequent bone marrow aspiration found an active bone marrow. He was also found to have low titers of both antinuclear antibody (ANA) and anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody. He was tested negative for the lupus anticoagulants (LA) and anti-cardiolipin (anti-CL) antibody. He was commenced on hydroxychloroquine and tapering doses of oral steroid. Two years later, the disease became quiescent and he had been drug free since.
In 2001, he was hospitalized for exertional breathlessness and retrosternal chest discomfort. Physical examination was unremarkable. His chest radiography (CXR), electrocardiogram (ECG), and cardiac enzymes were all normal. A subsequent cardiopulmonary stress test showed evidence of ischemic heart disease. He was commenced on aspirin and oral nitrate. From 2001 to 2005, he remained asymptomatic. In 2005, he discontinued all his medications and a year later, he defaulted his medical appointments. During his last outpatient visit before his default, he was symptom free but his anti-dsDNA antibody level was 143 IU/ml (reference range, <55 IU/ml).
In August 2009, he, 52 years old at that time, presented to the casualty department for severe retrosternal chest
Introduction
Heart disease is the third leading cause of death in Hong Kong, accounting for 13.2% of all deaths in 2015 (Department of Health). Coronary heart disease (CHD) accounts for two-third (66.6%) of the deaths attributed to heart disease. Atherosclerosis is the underlying pathology in CHD. It is an inflammatory process that begins with endothelial damage, causing plaque formation, which leads to hardening and narrowing of the coronary arteries. Risk factors such as aging, cigarette smoking, obesity, hypertension, diabetes, and hypercholesterolemia have all been well researched. In patients with systemic lupus erythematosus (SLE), atherosclerosis is accelerated. The pathogenesis is not completely understood. The abovementioned risk factors, current glucocorticoid pain. His ECG showed new ST segment depression over inferior and anterolateral leads and his troponin I level was raised to 3.17 ng/ml (reference range, <0.50 ng/ ml). Transthoracic echocardiography (TTE) revealed hypokinetic segments over the distal, anteroseptal, inferior, and lateral regions. The left ventricular (LV) contraction was fair to satisfactory. He never smoked and no prior history of diabetes mellitus or hyperlipidemia. He was commenced on a combination of subcutaneous low-molecular-weight heparin and oral dual antiplatelet agents. With regards to his SLE, he has been symptom free since 2005. Biochemical workup showed anti-dsDNA antibody was greater than 200 IU/ml. The Erythrocyte sedimentation rate (ESR) was normal. His activated partial thromboplastin time (APTT) was prolonged to 54.6 s (26-39 s). LA and anti-β2 glycoprotein 1 (anti-β2 GP1) antibody were negative. However, anti-CL Immunoglobulin G (IgG) antibody level was raised to 68.6 IgG phospholipid (GPL) units (reference range, <20 GPL units).
Percutaneous coronary angiogram was conclusive of triple vessel disease. An early coronary artery bypass graft operation was performed, which was uneventful. He was commenced on cardiprin, simvastatin, beta-blocker, and calcium channel blocker and has been under the care of the cardiologists since.
He remained well for 8 years until August 2017, when he was hospitalized for exertional breathlessness and skin rash. Blood tests revealed pancytopenia and lymphopenia. His anti-dsDNA antibody was greater than 200 IU/ml. His CXR was normal and ECG showed no acute ischemic changes. He was resumed on prednisolone and hydroxychloroquine for his lupus flare. At the time of discharge, the results of tests regarding LA, anti-CL, and anti-β2 GP1 antibodies were pending.
Three days after discharge, he was readmitted for exertional breathlessness and dizziness. Physical examination was unremarkable. Preliminary blood tests, ECG, and CXR were all normal. Contrast computer tomography (CT) of his thorax was performed, which did not reveal pulmonary embolism, ground glass change, and fibrosis. TTE showed impaired LV contraction with an ejection fraction of 51%. There were multiple hypokinetic segments over the anterior, anteroseptal, and septal walls, but there was no pericardial effusion or major valvular lesions. CT coronary angiogram was performed. It demonstrated total occlusion of the venous graft to RCA (right coronary artery) shortly after its anastomosis with the aorta. The venous grafts to LAD (left anterior descending) and LCx (left circumflex) arteries were patent. The anti-CL IgG antibody test performed during the last admission was moderately raised to 77.3 GPL units while LA and anti-β2 GP1 antibody were negative. In view of the above findings, he was treated with warfarin on top of aspirin. One month later, he underwent diagnostic coronary angiogram, in which identified distal left main coronary artery 30% stenosis, chronic total occlusion (CTO) at proximal LAD, proximal to distal LCx 80% stenosis, patent saphenous vein graft (SVG) to LAD but blocked SVG to OMs (obtuse marginal) branch and posterior descending artery. Ad hoc percutaneous coronary stenting (PTCS) to the LCx stenosis was performed. Two months later, he underwent another staged PTCS to tackle other occluded coronary vessels. He was planned to continue dual antiplatelets for 1 year. Clopidogrel will be taken off and replaced by warfarin. He was advised to take lifelong aspirin.
In summary, this case highlights a male patient with SLE with no other cardiovascular risk factors, who developed arterial thrombosis causing triple vessels disease, requiring coronary artery bypass graft (CABG). He developed post-CABG venous graft occlusion. Although the two anti-CL IgG antibody tests were performed over a span of 8 years (in year 2009 and 2017, respectively), the persistently moderately raised titers together with his clinical presentation is highly suggestive of a case of APS.
Discussion

Morbidity and mortality in APS
There appears to be racial differences in the thrombotic manifestation of APS. In the prospective 10-year Europhospholipid cohort study, involving 1000 patients, 36% of the patients had SLE. The most common clinical manifestation was thrombosis, presenting as stroke (5.3%), transient ischemic attack (4.7%), deep vein thrombosis (4.3%), and pulmonary embolism (3.5%). Myocardial infarction accounted for 1.9% of the total cohort. Other non-criteria APS manifestations were thrombocytopenia (8.7%), Livedo reticularis (8.1%), autoimmune hemolytic anemia (4%), valve thickening/dysfunction, vegetations (4.6%), epilepsy (3.2%), skin ulcers (3.1%), and superficial thrombophlebitis (1.7%) [1] . There were 188 pregnancies among 127 women during the 10-year period. A total of 72.9% of pregnancies succeeded in having live births. The most common obstetric complication was early pregnancy loss (<10 weeks), which accounted for 16.5% of all the pregnancies. Other obstetric complications included preeclampsia/eclampsia (6.4%) and late pregnancy loss (>10 weeks) (4.8%). Fetal morbidities were prematurity birth (48.2%) and intrauterine growth restriction (26.3%). The most common causes of mortality were bacterial infection (21.5%), myocardial infarction (13.9%), malignancy (13.9%), stroke (11.8%), hemorrhage (10.7%), catastrophic APS (5.4%), and pulmonary embolism (5.4%) [1] .
While in a Chinese cohort of 679 patients with SLE in Hong Kong, 44 patients (6.5%) had APS. APS manifestations were ischemic stroke (55%), deep vein thrombosis and/or pulmonary embolism (32%), obstetric APS (14%), peripheral vascular disease (9%), and retinal artery thrombosis (2%). Myocardial infarction or acute coronary syndrome accounts for 11% of the APS clinical manifestations. The patients with APS were more likely to die from the thrombosis event, particularly myocardial infarction, than patients without APS [2] .
Outcome of patients with APS undergoing PCI
Accelerated atherosclerosis has been found to occur more frequently in patients with APS compared to general population. Over time, patients developed coronary artery disease causing acute coronary syndrome. In this setting, percutaneous coronary intervention (PCI) is the most common invasive cardiovascular procedure performed. In a meta-analysis, the long-term cardiovascular adverse outcomes after PCI were compared between patients with APS and/or SLE and those without. Mortality, myocardial infarction, major cardiac events, and repeated revascularization were significantly higher in the APS and/or SLE group [3] .
Pathogenesis of APS
What is the reason behind the accelerated atherosclerosis in patients with APS? Why does this group of patients behave worse than the general population after cardiac intervention? Possible explanations may be derived from the complex pathogenesis of APS. First, the presence of circulating antiphospholipid (anti-PL) antibodies does not necessarily lead to thrombotic disease manifestation. Underlying host susceptibility is a prerequisite for disease development. In susceptible individuals, when anti-PL antibodies bind to the endothelial β2-GP1 receptors, it causes endothelial cells dysfunction, resulting in thrombosis, accelerated atherosclerosis, and subsequent cardiovascular events [4] . This manifestation is believed to be triggered by a second hit in the form of inflammatory insults such as infection or trauma, which increases the expression of endothelial β2-GP1 receptors, potentiating the binding of anti-PL antibodies to the receptors that trigger the thrombotic cascade leading to final presentation.
The binding of anti-PL antibodies onto the endothelial β2-GP1 receptors results in endothelial dysfunction by inhibiting the production and release of endotheliumderived nitric oxide (NO) from the endothelial NO synthase. Endothelial-derived NO is essential in maintaining the endothelium in a healthy state. Inadequate NO leads to leukocyte-endothelial cell adhesion, adhesion molecule expression, and tissue factor production; all of these result in thrombus formation [5] [6] [7] .
Endothelial cells dysfunction also directly causes vasculopathy. Studies carried out by Canaud et al. found that anti-CL and anti-β2-GP1 antibodies activate the phosphatidylinositol 3-kinase-Protein Kinase B (Pl3K-Akt) pathway and the mammalian target of rapamycin complex (mTORC). It is through this mechanism that the antibodies induce endothelial cells proliferation and intimal hyperplasia [8, 9] .
Studies found that apart from causing endothelial dysfunction and vasculopathy, circulating anti-CL and anti-β2-GP1 antibodies assist macrophages to internalize low-density lipoprotein-β2-GP1 complexes to form foam cells, which subsequently develop into atherosclerotic plaque [10] [11] [12] . In addition, circulating anti-CL antibodies bind to β2-GP1 receptors on platelets, causing platelet activation, platelet aggregation, and thrombosis [13] .
Studies have also found that anti-PLs antibodies activate the classical complement system to exert a thrombogenic effect. In mice models, C3 and C5 are essential for anti-PLs associated thrombosis [14] . When C5a interacts with its receptor C5aR to form C5a-C5aR complex, it stimulates the recruitment and activation of neutrophils as well as mediates endothelial cells activation [15] . The complex also increases tissue factor expression, which is believed to be one of the mechanisms underlying anti-PL antibody-related-thrombosis [16] .
Risk stratification for patients with APS
After we have understood the pathogenesis underlying APS-related thrombosis and its associated morbidity and mortality, is it possible to identify at-risk groups and treat them early?
There are a number of risk factors identified. First, different anti-PLs antibody profiles are associated with different thrombotic risks. LA positivity, triple positivity (LA plus anti-CL antibody plus anti-β2-GP1 antibody), and isolated persistently positive anti-CL antibody at medium-high titer are regarded as high-risk groups, whereas intermittently isolated positive anti-CL antibody and low-to-medium titer of anti-β2-GP1 antibody are regarded as low-risk groups [17] . Second, the presence of traditional cardiovascular risk factors such as hypertension, hyperlipidemia, smoking, and the use of estrogen increase thrombotic risk. Third, SLE by itself is a risk factor for thrombosis. Thus SLE in patients with APS further increases their thrombotic risk.
A novel risk assessment score, the Global APS Score (GAPSS), seems to be a useful risk stratification tool. This score was derived from the combination of independent risk factors for thrombosis and pregnancy loss in a cohort of 211 patients with SLE [18] . With the help of statistical methods, six factors, each assigned with different weighted points, have been identified: anti-CL IgG/Immunoglobulin M (IgM) anti-β2-GP1 IgG/IgM, Lupus anticoagulant, antiprothrombin/phosphatidylserine complex IgG/IgM, hyperlipidemia, and arterial hypertension [18] . The score was prospectively validated in 51 SLE cases. The GAPSS is higher in patients with vascular events, whereas in those without such events, the GAPSS remains unchanged. The increase in GAPSS during follow-up was significantly associated with a higher risk of vascular events [19] . This score was also validated in a primary APS cohort [20] .
Treatment -primary prophylaxis
As thrombosis is the primary pathology of APS, to tackle the disease, the aim should be preventing thrombosis. According to the 13th International Congress on Antiphospholipid Antibodies Prevention and Management Task Force recommendations, a strict control of cardiovascular risk factors should be adopted in patients with high-risk anti-PLs profile irrespective of the existence of prior thrombosis, concomitant SLE, or other additional APS features [17] .
Regarding the use of aspirin as primary prophylaxis, it is still controversial. Studies have shown that the use of aspirin significantly reduces the risk of first thrombosis in asymptomatic anti-PLs positive patients, patients with SLE, and patients with obstetric APS [21, 22] . Laurent Arnaud and others conducted an analysis of patient-level data from five international cohorts to examine the effect of low-dose aspirin on the risk of first thrombotic event in patients with aPL antibodies. They pooled the data collected from 497 patients and 79 first thrombotic events. After adjusting on cardiovascular risk factors, aPL antibody profiles, and the treatment with hydroxychloroquine, the risk of first thrombosis in those treated with aspirin was lower than the untreated cases. [21] . On the contrary, the Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) trial-a randomized, placebo controlled study to determine the efficacy of aspirin in primary prevention of thrombosis in asymptomatic aPL positive patients-failed to demonstrate any benefit of aspirin [23] . On the basis of the above conflicting evidence, universal use of aspirin as primary thromboprophylaxis cannot be recommended for asymptomatic aPL carriers. While for those with high-risk aPL profiles, coexisting cardiovascular risk factors, or SLE, the use of aspirin as prophylaxis should be considered [17] .
While in patients with SLE with high-risk antiPLs profile, long-term use of hydroxychloroquine is recommended. Hydroxychloroquine has a diseasemodifying effect in patients with SLE. In asymptomatic anti-PLs antibody positive patients, its use is associated with the reduction in thrombotic events [24] .
The "clinically significant" anti-PLs positive patients should be regarded as high-thrombotic-risk patients when they are in high-risk situations such as surgery and prolonged immobilization. Both physical and pharmacologic intervention should be used to prevent thrombosis. General physical measures such as compression stocking and intermittent pneumatic compression devices should be used to prevent venous stasis and to promote venous return. Pharmacologic measure such as administration of short-acting anticoagulant (low-molecular-weight heparin or unfractionated heparin) is recommended for those who undergo selected surgeries that are associated with thrombotic risk (Table 1) . In general, a therapeutic-dose regimen for approximately 8-10 days or until the patient is ambulatory is advised. However, the dose, timing, and duration of anticoagulation therapy should be individualized depending on the type of surgery, the mode of anesthesia, the patients' bleeding risk, the procedures' bleeding risk, the duration of immobility, and so on [25] .
Treatment-secondary prophylaxis
For secondary thromboprophylaxis, anticoagulation remains as the core treatment in patients with APS.
In venous thrombosis, the use of anticoagulation therapy with a target international normalized ratio (INR) of 2.0-3.0 is recommended as an effective treatment to prevent recurrent event. In two randomized controlled trials, high-intensity anticoagulation (target INR of 3.0-4.0 and 3.0-4.5, respectively) is not better than the moderate intensity warfarin in preventing recurrence [26, 27] .
While in arterial thrombosis, there is a lack of good quality randomized controlled trial to support the best treatment regimen, some expert center recommends highintensity warfarin regimen, with targeted INR of >3.0. This recommendation is supported by a systemic review. It concluded from observational studies that patients with APS who got arterial or recurrent events are at high risk of recurrence when treated with anticoagulation target at INR of 2.0-3.0. For those with INR of >3.0, the rate of recurrent thrombosis is low [28] . Although high-intensity warfarin treatment seems to be a more effective option, we have to balance clinical efficacy against bleeding risk. Study showed that when target INR was >4.0-5.0, the risk of major bleeding increases sharply [29] . Judging from the evidence, we must take into account the factors associated with higher risk of bleeding, such as older age, poly-pharmacy, history of severe bleeding, and underlying malignancy while we consider to intensify anticoagulation treatment in patients with arterial APS.
Apart from high-intensity anticoagulation, combined antiaggregant-anticoagulant therapy with targeted INR of 2.0-3.0 may be considered as an option [17] . In a small randomized controlled trial conducted by the Japanese, which recruited 20 patients with APS and stroke, combined warfarin (target INR of 2.0-3.0) and low-dose aspirin was statistically more effective as a secondary preventive treatment than aspirin alone [30] . Although this study is a randomized one, it is rather small scale with significant limitations. Large and well-designed study is needed to evaluate the efficacy of combination treatment regimen.
For patients with definite APS who are at risk of developing thrombosis, lifelong anticoagulant therapy is warranted. This is supported by a retrospective study showing significant recurrence of thrombosis soon after discontinuing anticoagulant treatment [31] .
The role and efficacy of novel oral anticoagulants (NOACs) in APS is still not well defined. The RAPS (Rivaroxaban Versus Warfarin to Treat Patients With Thrombotic Antiphospholipid Syndrome, With or without Systemic Lupus Erythematosus) trial, which is a randomized, controlled, non-inferiority trial, studied the outcomes of using warfarin versus rivaroxaban in treating venous thrombosis in patients with APS, with or without SLE. A laboratory surrogate marker (percentage change in endogenous thrombin potential from randomization to day 42) was used as the primary outcome measure. Rivaroxaban did not reach the non-inferiority threshold from the laboratory surrogate standpoint, but there was no increase in thrombotic risk when compared to warfarin [32] . There are two other ongoing randomized trials studying apixaban and rivaroxaban as an alternative treatment to warfarin in APS. With the current evidence, the Task Force recommends the use of NOACs only in patients who are allergic or intolerant to warfarin or in patients with poor control of anticoagulation [33] .
Statins, which are potent inhibitors of cholesterol synthesis, have been shown to be beneficial in primary and secondary prevention of coronary heart disease. In addition to their lipid lowering effect, they have immunemodulatory, anti-inflammatory and antithrombotic properties [34] . Both simvastatin and fluvastatin suppress endothelial activation induced by anti-β2-GP1 antibodies [35] . Fluvastatin has been shown to suppress the expression of upregulated tissue factor by anti-PLs on endothelial [33] . Concerning cell-depletion therapy, rituximab (RTX) in APS, a retrospective analysis was carried out in Taiwan to evaluate the efficacy of RTX in 800 hospitalized SLE cases. There were 63 SLE-associated APS cases, 6 of whom had secondary warfarin failure. The six refractory patients were treated with RTX infusion. The regimens were 2 in 1000-or 500-mg doses fortnightly with a complete depletion of peripheral B cells. With the addition of RTX, none had recurrent thrombosis. After RTX infusion, LA disappeared. The level of anti-CL IgM decreased significantly. However, there was no response in anti-β2-GP1 titer. In all, their lupus activity decreased. Infection-related complications were bronchitis and urinary tract infection [37] .
As complement activation is one of the mechanisms underlying thrombosis in APS, complement inhibitory therapy may be a potential therapeutic option. Eculizumab is a monoclonal antibody targeted at C5 protein. It blocks the cleavage of C5 into C5a and C5b, inhibiting the formation of membrane attack complex. A case report demonstrated promising results of eculizumab in treating a refractory APS patient resistant to anticoagulation, immunosuppressive therapy, plasmapheresis, and RTX [38] . Another case report showed improvement of post kidney transplant thrombotic microangiopathy in an patient with APS treated with eculizumab [39] . However, more clinical data is needed to support and confirm its clinical efficacy before it can be recommended as a treatment option.
In summary, our case illustrates that thrombosis in APS carries significant morbidity. Premature atherosclerosis occurs early and is usually aggressive, which may result in mortality. Patients with APS and arterial thrombosis causing myocardial infarction behave worse than non-APS patients, despite PCI. Risk stratification is indicated to identify high-risk cases, which warrant early primary thromboprophylaxis. With existing evidence, warfarin still remains as the fundamental treatment for established thrombosis in APS. Rituximab demonstrates promising clinical efficacy in refractory cases. Rheumatologists and immunologists look forward to novel treatments options targeted at the molecular level.
